Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-23

    Virtual Booth

    An Enquiry

    Menu

    Tinlarebant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Belite Gets Breakthrough For Tinlarebant In Stargardt Diseases
    Belite Gets Breakthrough For Tinlarebant In Stargardt Diseases

    21 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/21/3085441/0/en/Belite-Bio-Announces-FDA-Granting-of-Breakthrough-Therapy-Designation-for-Tinlarebant-for-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    21 May 2025
    Share Share
    Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease
    Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3033536/0/en/Belite-Bio-Announces-Interim-Analysis-Results-from-the-Pivotal-Global-Phase-3-DRAGON-trial-of-Tinlarebant-in-Adolescent-Stargardt-Disease-Subjects.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    Belite Bio Announces Doses First Patient In DRAGON II Trial
    Belite Bio Announces Doses First Patient In DRAGON II Trial

    10 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/10/2943626/0/en/Belite-Bio-Announces-First-Patient-Dosed-in-Phase-2-3-DRAGON-II-Trial-of-Tinlarebant-for-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    10 Sep 2024
    Share Share
    Belite Bio Reports Q2 2024 Results And Corporate Update
    Belite Bio Reports Q2 2024 Results And Corporate Update

    09 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/09/2927935/0/en/Belite-Bio-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    09 Aug 2024
    Share Share
    Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant
    Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant

    12 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/12/2897299/0/en/Belite-Bio-Receives-Sakigake-Pioneer-Drug-Designation-of-Tinlarebant-for-Stargardt-Disease-in-Japan.html

    GLOBENEWSWIRE
    12 Jun 2024
    Share Share
    Belite Bio Q1 2024 Financials, Corporate Update
    Belite Bio Q1 2024 Financials, Corporate Update

    13 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2881001/0/en/Belite-Bio-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    13 May 2024
    Share Share